Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 23

1.

Reporting noninferiority trials--reply.

Pocock SJ, Piaggio G, Altman DG; CONSORT Group.

JAMA. 2013 Apr 17;309(15):1585. doi: 10.1001/jama.2013.3095. No abstract available.

PMID:
23592099
[PubMed - indexed for MEDLINE]
2.

An orwellian discourse on the meaning and measurement of noninferiority.

Diamond GA, Kaul S.

Am J Cardiol. 2007 Jan 15;99(2):284-7. Epub 2006 Nov 27. Review.

PMID:
17223435
[PubMed - indexed for MEDLINE]
3.

Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials.

Kaul S, Diamond GA.

Prog Cardiovasc Dis. 2007 Jan-Feb;49(4):284-99. Review.

PMID:
17185116
[PubMed - indexed for MEDLINE]
4.

The quality of reports of randomized trials in multiple sclerosis: a review.

Signori A, Baccino A, Sormani MP.

Mult Scler. 2012 Jun;18(6):776-81. doi: 10.1177/1352458512444327. Epub 2012 Apr 11. Review.

PMID:
22495947
[PubMed - indexed for MEDLINE]
5.

Drug safety assessment in clinical trials: methodological challenges and opportunities.

Singh S, Loke YK.

Trials. 2012 Aug 20;13:138. doi: 10.1186/1745-6215-13-138. Review.

PMID:
22906139
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis.

Rheims S, Perucca E, Cucherat M, Ryvlin P.

Epilepsia. 2011 Feb;52(2):219-33. doi: 10.1111/j.1528-1167.2010.02915.x. Epub 2011 Jan 26. Review.

PMID:
21269281
[PubMed - indexed for MEDLINE]
7.

Reporting on covariate adjustment in randomised controlled trials before and after revision of the 2001 CONSORT statement: a literature review.

Yu LM, Chan AW, Hopewell S, Deeks JJ, Altman DG.

Trials. 2010 May 18;11:59. doi: 10.1186/1745-6215-11-59. Review.

PMID:
20482769
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Statistical considerations for noninferiority/equivalence trials in vaccine development.

Wang WW, Mehrotra DV, Chan IS, Heyse JF.

J Biopharm Stat. 2006;16(4):429-41. Review.

PMID:
16892905
[PubMed - indexed for MEDLINE]
9.

Statistical issues and recommendations for noninferiority trials in oncology: a systematic review.

Tanaka S, Kinjo Y, Kataoka Y, Yoshimura K, Teramukai S.

Clin Cancer Res. 2012 Apr 1;18(7):1837-47. doi: 10.1158/1078-0432.CCR-11-1653. Epub 2012 Feb 8. Review.

PMID:
22317762
[PubMed - indexed for MEDLINE]
Free Article
10.

Statistical considerations for the next generation of clinical trials.

Wu W, Shi Q, Sargent DJ.

Semin Oncol. 2011 Aug;38(4):598-604. doi: 10.1053/j.seminoncol.2011.05.014. Review.

PMID:
21810519
[PubMed - indexed for MEDLINE]
11.

Consistency in the analysis and reporting of primary end points in oncology randomized controlled trials from registration to publication: a systematic review.

You B, Gan HK, Pond G, Chen EX.

J Clin Oncol. 2012 Jan 10;30(2):210-6. doi: 10.1200/JCO.2011.37.0890. Epub 2011 Dec 12. Review.

PMID:
22162583
[PubMed - indexed for MEDLINE]
Free Article
12.

Non-inferiority study design: lessons to be learned from cardiovascular trials.

Head SJ, Kaul S, Bogers AJ, Kappetein AP.

Eur Heart J. 2012 Jun;33(11):1318-24. doi: 10.1093/eurheartj/ehs099. Epub 2012 May 7. Review.

PMID:
22564354
[PubMed - indexed for MEDLINE]
Free Article
13.

Statistical issues in interpreting clinical trials.

DeMets DL.

J Intern Med. 2004 May;255(5):529-37. Review.

PMID:
15078496
[PubMed - indexed for MEDLINE]
14.

Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension.

Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group.

JAMA. 2013 Feb 27;309(8):814-22. doi: 10.1001/jama.2013.879.

PMID:
23443445
[PubMed - indexed for MEDLINE]
15.

End points and clinical trial design in pulmonary arterial hypertension.

McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galiè N, Gibbs JS, Kim NH, Oudiz RJ, Peacock A, Provencher S, Sitbon O, Tapson VF, Seeger W.

J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S97-107. doi: 10.1016/j.jacc.2009.04.007. Review.

PMID:
19555863
[PubMed - indexed for MEDLINE]
Free Article
16.

Reporting attrition in randomised controlled trials.

Dumville JC, Torgerson DJ, Hewitt CE.

BMJ. 2006 Apr 22;332(7547):969-71. Review. No abstract available.

PMID:
16627519
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Reporting of harm in randomized controlled trials published in the urological literature.

Breau RH, Gaboury I, Scales CD Jr, Fesperman SF, Watterson JD, Dahm P.

J Urol. 2010 May;183(5):1693-7. doi: 10.1016/j.juro.2010.01.030. Epub 2010 Mar 17. Review.

PMID:
20299044
[PubMed - indexed for MEDLINE]
18.

Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field.

Wittkop L, Smith C, Fox Z, Sabin C, Richert L, Aboulker JP, Phillips A, Chêne G, Babiker A, Thiébaut R; NEAT-WP4.

Clin Trials. 2010 Feb;7(1):19-35. doi: 10.1177/1740774509356117. Review.

PMID:
20156955
[PubMed - indexed for MEDLINE]
19.

Pitfalls and biases in the reporting and interpretation of the results of clinical trials.

Parmar MK.

Lung Cancer. 1994 Mar;10 Suppl 1:S143-50. Review.

PMID:
8087503
[PubMed - indexed for MEDLINE]
20.

The adequacy of reporting randomized, controlled trials in the evaluation of antidepressants.

Streiner DL, Joffe R.

Can J Psychiatry. 1998 Dec;43(10):1026-30. Review.

PMID:
9868568
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk